ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

AACR, Kellogg’s Co. Sponsor Award

January 5, 1996

Data On CT Screening For Lung Cancer Raises Questions About DOD Program

April 23, 2010

New Prostate Cancer Detection Group to Study Ultrasound

March 6, 1987

Nine More state To Pay For Cancer Treatment Of CDC-Screened Women.

September 7, 2001

AACI To Seek Line Item For Centers In Cancer Act Renewal

January 18, 1980

Clinical Oncology Program Has Top Priority Fink Says

February 9, 1979